PE20121689A1 - Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos - Google Patents

Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos

Info

Publication number
PE20121689A1
PE20121689A1 PE2012000444A PE2012000444A PE20121689A1 PE 20121689 A1 PE20121689 A1 PE 20121689A1 PE 2012000444 A PE2012000444 A PE 2012000444A PE 2012000444 A PE2012000444 A PE 2012000444A PE 20121689 A1 PE20121689 A1 PE 20121689A1
Authority
PE
Peru
Prior art keywords
glycosilation
advanced
receiver
final products
polypeptides
Prior art date
Application number
PE2012000444A
Other languages
English (en)
Inventor
Jochen Huber
Francis Blanche
Tarik Dabdoubi
Fabienne Soubrier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/en
Priority claimed from EP09290845A external-priority patent/EP2319871A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20121689A1 publication Critical patent/PE20121689A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL QUIMERICO HUMANIZADO QUE SE UNE AL RECEPTOR PARA PRODUCTOS FINALES DE GLICOSILACION AVANZADA (RPFGA) QUE COMPRENDE A) UN DOMINIO VARIABLE DE CADENA LIGERA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº 1 A 23 O UNA VARIANTE FUNCIONALMENTE ACTIVA; B) UN DOMINIO VARIABLE DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº 24 A 46 O UNA VARIANTE FUNCIONALMENTE ACTIVA; Y C) UN DOMINIO CONSTANTE DE INMUNOGLOBULINA DE CADENA PESADA TAL COMO IgM, IgG1, IgG2, IgG3, IgG4, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, DIABETES, AMILOIDOSIS, ENFERMEDAD DE ALZHEIMER
PE2012000444A 2009-10-09 2010-10-08 Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos PE20121689A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290778A EP2308896A1 (en) 2009-10-09 2009-10-09 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845A EP2319871A1 (en) 2009-11-05 2009-11-05 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Publications (1)

Publication Number Publication Date
PE20121689A1 true PE20121689A1 (es) 2012-12-14

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000444A PE20121689A1 (es) 2009-10-09 2010-10-08 Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos

Country Status (19)

Country Link
US (1) US20120282637A1 (es)
EP (1) EP2486058A1 (es)
JP (1) JP2013507115A (es)
KR (1) KR20120089863A (es)
CN (1) CN102686611A (es)
AU (1) AU2010305374A1 (es)
BR (1) BR112012007821A2 (es)
CA (1) CA2777237A1 (es)
CL (1) CL2012000886A1 (es)
CR (1) CR20120139A (es)
EC (1) ECSP12011787A (es)
IL (1) IL218968A0 (es)
MA (1) MA33661B1 (es)
MX (1) MX2012004090A (es)
PE (1) PE20121689A1 (es)
RU (1) RU2558301C2 (es)
TN (1) TN2012000138A1 (es)
WO (1) WO2011042548A1 (es)
ZA (1) ZA201202099B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (ja) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 アミロイド前駆体タンパク質のα－セクレターゼ切断後のＣ末端側断片の切断面を特異的に認識する抗体及びその利用
US11668721B2 (en) 2013-06-04 2023-06-06 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
MX371496B (es) 2013-08-30 2020-01-31 Immunogen Inc Anticuerpos y ensayos para la detección del receptor 1 de folato.
EP3633381A3 (en) 2013-12-05 2020-07-29 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3207062A1 (en) * 2014-10-16 2017-08-23 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
WO2016070001A1 (en) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
JP6857138B2 (ja) 2015-05-18 2021-04-14 アジェンシス，インコーポレイテッド Ａｘｌタンパク質に結合する抗体
US20180355033A1 (en) 2015-06-10 2018-12-13 Dana-Farber Cancer Institute, Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2016201319A1 (en) * 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
SG11201800127WA (en) * 2015-09-08 2018-03-28 Eisai R&D Man Co Ltd Anti-epha4 antibody
CA2994888A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN108570106B (zh) * 2017-03-10 2021-07-16 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
BR112020001679A2 (pt) 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anticorpos anti-cd47 e usos dos mesmos
EP3773718A4 (en) 2018-04-06 2022-01-19 aTyr Pharma, Inc. COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
JP2022539178A (ja) * 2019-06-26 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ１ｒａｐ結合タンパク質
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
TR200302015T4 (tr) 2000-06-08 2004-01-21 Intercell Biomedizinische Forschungs-Und Entwicklungs Ag İmüno-uyarıcı oligodeoksinükleotitler
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
EP1309345A2 (en) 2000-08-17 2003-05-14 Cistem Biotechnologies GmbH Cathelicidins as vaccine adjuvants
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
ATE366308T1 (de) 2001-05-21 2007-07-15 Intercell Ag Immunostimulierende oligodeoxyribonuklein moleküle
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
KR20090003308A (ko) * 2006-03-02 2009-01-09 온코세라피 사이언스 가부시키가이샤 Ｒｅｇ４ 단백질을 이용한 췌장암 진단 방법
CN101448857A (zh) * 2006-03-21 2009-06-03 惠氏公司 预防和治疗淀粉样蛋白生成疾病的方法
RU2008134135A (ru) * 2006-03-21 2010-04-27 Вайет (Us) Соединения-антагонисты белка rage и способы их применения
EP2035456A1 (en) * 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
BRPI0911758A8 (pt) * 2008-05-09 2017-10-10 Abbott Lab Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos

Also Published As

Publication number Publication date
ECSP12011787A (es) 2012-10-30
JP2013507115A (ja) 2013-03-04
MX2012004090A (es) 2012-04-20
CL2012000886A1 (es) 2012-12-14
KR20120089863A (ko) 2012-08-14
TN2012000138A1 (en) 2013-09-19
US20120282637A1 (en) 2012-11-08
EP2486058A1 (en) 2012-08-15
MA33661B1 (fr) 2012-10-01
CN102686611A (zh) 2012-09-19
ZA201202099B (en) 2012-11-28
BR112012007821A2 (pt) 2017-05-30
CA2777237A1 (en) 2011-04-14
AU2010305374A1 (en) 2012-05-03
WO2011042548A1 (en) 2011-04-14
IL218968A0 (en) 2012-07-31
RU2012118598A (ru) 2013-11-20
CR20120139A (es) 2012-07-13
RU2558301C2 (ru) 2015-07-27

Similar Documents

Publication Publication Date Title
PE20121689A1 (es) Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
PE20090689A1 (es) Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20121397A1 (es) Anticuerpos especificos para cadherina-17
PE20060287A1 (es) INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20131209A1 (es) Anticuerpos anti-fap
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20140247A1 (es) Anticuerpos anti-cd38
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PE20091342A1 (es) Inmunoglobulinas
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
PE20110771A1 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
TW200745164A (en) Gene recombination antibodies composition
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
PE20130159A1 (es) Anticuerpos anti-cd40
PE20141045A1 (es) Proteinas de union a bcma (cd269/tnfrsf17)
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
PE20141017A1 (es) Anticuerpos del cea
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
PE20081399A1 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal